Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Early detection of prostate cancer: AUA Guideline.

Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL.

J Urol. 2013 Aug;190(2):419-26. doi: 10.1016/j.juro.2013.04.119. Epub 2013 May 6.

2.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

3.

Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.

Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2013 May 21;158(10):761-9. doi: 10.7326/0003-4819-158-10-201305210-00633.

PMID:
23567643
4.

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.

Hayes JH, Barry MJ.

JAMA. 2014 Mar 19;311(11):1143-9. doi: 10.1001/jama.2014.2085. Review.

PMID:
24643604
5.

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.

Can J Urol. 2011 Oct;18(5):5875-83. Review.

6.

American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee.

CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. doi: 10.3322/caac.20066. Epub 2010 Mar 3. Review.

7.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

8.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team.

J Natl Cancer Inst. 2005 Mar 16;97(6):433-8.

9.

Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.

Melnikow J, LeFevre M, Wilt TJ, Moyer VA.

Med Care. 2013 Apr;51(4):301-3. doi: 10.1097/MLR.0b013e31828a67d3.

PMID:
23481031
10.

The Japanese guideline for prostate cancer screening.

Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T.

Jpn J Clin Oncol. 2009 Jun;39(6):339-51. doi: 10.1093/jjco/hyp025. Epub 2009 Apr 4.

11.

Landmarks in prostate cancer screening.

Schröder FH.

BJU Int. 2012 Oct;110 Suppl 1:3-7. doi: 10.1111/j.1464-410X.2012.011428.x. Review.

12.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
13.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
14.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
15.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

16.

National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE.

Cancer. 2014 May 15;120(10):1491-8. doi: 10.1002/cncr.28600. Epub 2014 Feb 12.

17.

Risk stratification in prostate cancer screening.

Roobol MJ, Carlsson SV.

Nat Rev Urol. 2013 Jan;10(1):38-48. doi: 10.1038/nrurol.2012.225. Epub 2012 Dec 18. Review. Erratum in: Nat Rev Urol. 2013 May;10(5):248.

PMID:
23247693
18.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

19.

Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.

PMID:
23759326
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk